Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Inclusion Criteria: * Histologically confirmed solid tumor at original diagnosis that has failed standard therapy or for which no standard therapy exists * Patients must have a disease for which there is no known curative potential * Patients must meet the following criteria for bone marrow function: * Status post stem cell transplantation (SCT) * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 (transfusion independent) * Hemoglobin at least 8.0 g/dL (RBC transfusions allowed) * No lymphomas * No CNS tumors or known metastatic disease to the brain or spinal cord * Performance status - Karnofsky 50-100% (age 11 to 21) * Performance status - Lansky 50-100% (age 1 to 10) * At least 8 weeks * See Disease Characteristics * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * ALT no greater than 3 times ULN * No significant hepatic dysfunction * Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min * Creatinine, based on age, as follows: * Age 1 to 5: no greater than 0.8 mg/dL * Age 6 to 10: no greater than 1.0 mg/dL * Age 11 to 15: no greater than 1.2 mg/dL * Age 16 to 21: no greater than 1.5 mg/dL * No significant renal dysfunction * Shortening fraction at least 28% by echocardiogram * Ejection fraction at least 45% by MUGA * No significant pulmonary dysfunction * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No serious uncontrolled infections * No other end-organ dysfunction that would preclude study entry * No other clinically significant systemic illness * See Disease Characteristics * Recovered from prior immunotherapy * At least 1 week since prior growth factors or other biologic agents * At least 6 months since prior autologous SCT * At least 6 months since prior allogeneic bone marrow transplantation and recovered with no evidence of graft-versus-host disease * No concurrent immunomodulating agents * No concurrent prophylactic growth factors during the first course of the study * No concurrent immunotherapy or other biologic therapy * Recovered from prior chemotherapy * At least 2 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) * No prior life-time cumulative doxorubicin dose of more than 450 mg/m\^2 or equivalent * No other concurrent chemotherapy * Concurrent chronic steroids allowed * Recovered from prior radiotherapy * More than 2 weeks since prior localized palliative radiotherapy (small port) * More than 6 months since prior substantial radiotherapy to bone marrow (craniospinal radiotherapy, total body irradiation, or hemi-pelvic radiotherapy) * No concurrent radiotherapy * Concurrent chronic medications (e.g., narcotics or antiepileptics) allowed * No other concurrent investigational agents * No other concurrent cancer therapy